Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 10/20 | 0.60 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.55 |
| ▸ | KCNK5 | O95279 | 1/20 | 0.55 |
| ▸ | KCNK17 | Q96T54 | 1/20 | 0.55 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.55 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 3/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | NNMT | P40261 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13789490 | 0.92 | KCNA5 (0.51) | KCNA5KCNK3KCNK5KCNK17KCNK9 | |
| SCHEMBL12434016 | 0.91 | KCNA5 (0.68) | KCNA5KCNK3KCNK5KCNK17KCNK9 | |
| SCHEMBL13789493 | 0.83 | KCNA5 (0.60) | KCNA5KCNK3KCNK5KCNK17KCNK9 | |
| SCHEMBL2208881 | 0.80 | KCNA5 (0.70) | KCNA5KCNK3KCNK5KCNK17KCNK9 | |
| SCHEMBL2207907 | 0.79 | KCNA5 (0.82) | KCNA5KCNK3KCNA3 | |
| SCHEMBL2210715 | 0.79 | KCNA5 (0.82) | KCNA5KCNK3KCNA3 | |
| SCHEMBL2207911 | 0.79 | KCNA5 (0.82) | KCNA5KCNK3KCNA3 | |
| SCHEMBL12434018 | 0.79 | KCNA5 (0.64) | KCNA5KCNK3KCNK5KCNK17KCNK9 | |
| SCHEMBL12434042 | 0.77 | KCNA5 (0.71) | KCNA5KCNK3KCNK5KCNK17KCNK9 | |
| SCHEMBL12434044 | 0.77 | KCNA5 (0.74) | KCNA5KCNK3KCNK5KCNK17KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7982045-B2 | 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-07-19 | — | — | US | disclosed |
| US-7982045-B2 | 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-07-19 | — | — | US | disclosed |
| US-20090192096-A1 | 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-07-30 | — | — | US | disclosed |
| US-20090192096-A1 | 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-07-30 | — | — | US | disclosed |
| US-7514582-B2 | 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-04-07 | — | — | US | disclosed |
| US-7514582-B2 | 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192096-A1 | 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them | MLLT3, RYR2, CACNA1E | KCNA5 90/4885KCNK3 346/4885KCNK5 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.